Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study
Neal D. Shore, Karim S. Fizazi, Teuvo L.J. Tammela, Murilo de Almeida Luz et autres
BACKGROUND: In the phase 3 ARAMIS study (NCT02200614), darolutamide significantly improved metastasis-free survival in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Following the primary analysis, the study was unblinded, and placebo recipients were permitted to cross over to open-label darolutamide. Despite crossover, …
us, fr, fi, br, pe, ca, co, de (code pays fourni par la source)
2 citations
European Journal of Cancer